Tafasitamab combined with idelalisib or venetoclax in patients with CLL previously treated with a BTK inhibitor

References

• Thompson PA, Burger JA. Bruton's tyrosine kinase inhibitors: first and second generation agents for patients with chronic lymphocytic leukemia (CLL). Expert Opin Investig Drugs. 2018;27(1):31–42.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Hillmen P, O’Brien S, et al. Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab. Blood. 2019;133(19):2031–2042.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Furman RR, Coutre S, et al. The Bruton's tyrosine kinase (BTK) inhibitor ibrutinib (PCI-32765) promotes high response rate, durable remissions, and is tolerable in treatment naïve (TN) and relapsed or refractory (RR) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) patients including patients with high-risk (HR) disease: new and updated results of 116 patients in a phase Ib/II study. Blood. 2012;120(21):189.
   Web of Science ®Google Scholar
• IMBRUVICA (ibrutinib capsules). Summary of product characteristics, Janssen-Cilag International NV, Beerse, Belgium, 2019.
   Google Scholar
• Sharman JP, Egyed M, Jurczak W, et al. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. Lancet. 2020;395(10232):1278–1291.
   PubMed Web of Science ®Google Scholar
• Jain P, Keating M, Wierda W, et al. Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib. Blood. 2015;125(13):2062–2067.
   PubMed Web of Science ®Google Scholar
• Woyach JA, Ruppert AS, Heerema NA, et al. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med. 2018;379(26):2517–2528.
   PubMed Web of Science ®Google Scholar
• Mato AR, Roeker LE, Eyre TA, et al. A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL. Blood Adv. 2019;3(10):1568–1573.
   PubMed Web of Science ®Google Scholar
• VENCLEXTA (venetoclax tablets). Highlights of prescribing information, AbbVie Ltd, Maidenhead, UK, 2019.
   Google Scholar
• VENCLEXTA (venetoclax tablets). Summary of product characteristics, AbbVie Ltd, Maidenhead, UK, 2019.
   Google Scholar
• CALQUENCE (acalabrutinib capsules). Highlights of prescribing information, AstraZeneca UK Ltd., Luton, UK, 2017.
   Google Scholar
• ZYDELIG (idelalisib tablets). Highlights of prescribing information, Gilead Sciences Ltd., London, UK, 2020.
   Google Scholar
• ZYDELIG (idelalisib tablets). Summary of product characteristics, Gilead Sciences Ltd., London, UK, 2020.
   Google Scholar
• Ghia P, Pluta A, Wach M, et al. ASCEND: phase ill, randomized trial of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol. 2020;38(25):2849–2861.
   PubMed Web of Science ®Google Scholar
• Awan FT, Lapalombella R, Trotta R, et al. CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody. Blood. 2010;115(6):1204–1213.
   PubMed Web of Science ®Google Scholar
• Horna P, Nowakowski G, Endell J, et al. Comparative assessment of surface CD19 and CD20 expression on B-cell lymphomas from clinical biopsies: implications for targeted therapies. Blood. 2019;134(Suppl. 1):5345.
   Web of Science ®Google Scholar
• Horton HM, Bernett MJ, Pong E, et al. Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia. Cancer Res. 2008;68(19):8049–8057.
   PubMed Web of Science ®Google Scholar
• Woyach JA, Awan F, Flinn IW, et al. A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL. Blood. 2014;124(24):3553–3560.
   PubMed Web of Science ®Google Scholar
• Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia Updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111(12):5446–5456.
   PubMed Web of Science ®Google Scholar
• Furman RR, Sharman JP, Coutre SE, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014;370(11):997–1007.
   PubMed Web of Science ®Google Scholar
• Seymour JF, Kipps TJ, Eichhorst B, et al. Venetoclax–rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2018;378(12):1107–1120.
   PubMed Web of Science ®Google Scholar
• MabThera (rituximab injection). Summary of product characteristics, Roche Products Limited, Welwyn Garden City, UK, 2020.
   Google Scholar
• RITUXAN (rituximab injection). Highlights of prescribing information, Roche Products Limited, Welwyn Garden City, UK, 2020.
   Google Scholar
• GAZYVA (obinutuzumab injection). Summary of product characteristics, Roche Products Limited, Welwyn Garden City, UK, 2020.
   Google Scholar
• GAZYVA (obinutuzumab injection). Highlights of prescribing information, Roche Products Limited, Welwyn Garden City, UK, 2020.
   Google Scholar
• Woyach JA, Ruppert AS, Awan F, et al. A phase II study of the Fc engineered CD19 antibody MOR208 in combination with lenalidomide for patients with chronic lymphocytic leukemia (CLL). Blood. 2015;126(23):2953.
   Web of Science ®Google Scholar
• Woyach JA, Ruppert AS, Awan FT, et al. Updated results from a phase II study of the fc engineered CD19 antibody MOR208 in combination with lenalidomide for patients with chronic lymphocytic leukemia (CLL) and Richter’s transformation or ibrutinib for patients with ibrutinib-resistant clones. Blood. 2016;128(22):4386.
   Web of Science ®Google Scholar
• Ryman JT, Meibohm B. Pharmacokinetics of monoclonal antibodies. CPT Pharmacometr Syst Pharmacol. 2017;6(9):576–588.
   PubMedGoogle Scholar
• Jones JA, Mato AR, Wierda WG, et al. Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol. 2018;19(1):65–75.
   PubMed Web of Science ®Google Scholar
• Skarzynski M, Niemann CU, Lee YS, et al. Interactions between ibrutinib and anti-CD20 antibodies: competing effects on the outcome of combination therapy. Clin Cancer Res. 2016;22(1):86–95.
   PubMed Web of Science ®Google Scholar
• Rawstron A, Munir T, Brock K, et al. Ibrutinib and obinutuzumab in CLL: improved MRD response rates with substantially enhanced MRD depletion for patients with >1 year prior ibrutinib exposure. Blood. 2018;132(Suppl. 1):181.
   Web of Science ®Google Scholar
• Sharman JP, Banerji V, Fogliatto LM, et al. Phase 3 study of acalabrutinib combined with obinutuzumab or alone vs obinutuzumab plus chlorambucil in patients with treatment-naive chronic lymphocytic leukemia: results from ELEVATE TN. Blood. 2019;134(Suppl. 1):31.
   Web of Science ®Google Scholar